Perceptions of combination nicotine replacement therapy and vaporised nicotine product use for tobacco smoking cessation following discharge from alcohol and other drug residential withdrawal services: A qualitative analysis

<u>JOSHUA TRIGG</u>¹, JANE RICH², EDWINA WILLIAMS², AMANDA BAKER², NATALIE WALKER³, MARK DAGLISH⁴, CHRIS BULLEN³, NADINE EZARD^{5,6}, BILLIE BONEVSKI¹

¹Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, South Australia, Australia ²School of Medicine and Public Health, College of Medicine, Health and Wellbeing, University of Newcastle, NSW, Australia ³The National Institute for Health Innovation, School of Population Health, The University of Auckland, Auckland, New Zealand. ⁴Faculty of Medicine, University of Queensland, and Royal Brisbane and Women's Hospital, Queensland, Australia. ⁵Alcohol and Drug Service, St Vincent's Hospital Sydney, Australia. ⁶Faculty of Medicine, University of New South Wales, NSW, Australia

Presenter email: joshua.trigg@flinders.edu.au

Introduction and aims: Tobacco smoking is highly prevalent among alcohol and other drug (AOD) service clients in Australia (77%). Despite clients' interest in quitting smoking and nicotine replacement therapy, abstinence is infrequently sustained post-discharge. Vaporised nicotine products (VNP) are an alternative means of managing nicotine withdrawal after discharge from residential smoke-free clinical sites, which we are currently trialling. This study examined AOD service clients' experiences of combination nicotine replacement therapy (C-NRT) or VNP for smoking cessation post-discharge.

Method/approach: We interviewed a subset (n=31) of residential service users from the NEAT clinical trial (n=367), who used 12-week C-NRT or VNP with Quitline access for smoking abstinence post-discharge from a residential AOD withdrawal service. Participants aged ≥18 years who smoked tobacco and had not used a VNP in the past month described their health and social changes, tobacco cravings, nicotine use, Quitline experience, and barriers and facilitators to C-NRT or VNP for smoking cessation. We inductively analysed interview transcripts for salient themes.

Key Findings: C-NRT and VNP were feasible and acceptable for smoking cessation. C-NRT was useful for managing nicotine cravings, with inhalators having potential to address smoking behaviour. VNP use was viewed as effective for smoking cessation and managing cravings post-discharge, with some drawbacks for VNP (e.g., taste) and C-NRT (e.g., behavioural preferences). Quitline services received mixed support, as participants could access support via AOD counselling.

Discussions and Conclusions: Using C-NRT and VNPs for smoking cessation was considered generally acceptable by AOD service clients. Accessing suitable nicotine products for VNP use beyond the trial was a barrier to sustained abstinence.

Implications for Practice or Policy: Addressing experiential aspects of C-NRT and VNP use can inform services' support for smoking cessation approaches based on client suitability.

Disclosure of Interest Statement: Authors declare no conflicts of interest. Work was NHMRC funded (GNT1160245).